by marcbacon | Sep 22, 2022
Emyria Limited, a clinical stage biotech, is set to work with PsychoGenics, a specialist neuroscience preclinical drug discovery and contract research organization (CRO). Emyria and partner, the University of Western Australia, will start by screening five novel MDMA...
by marcbacon | Sep 22, 2022
By Vanessa Doctor, RN · Sep 22, 2022 · BioSpace It’s been a busy week across the clinical development space, with Alaunos Therapeutics, Satsuma Pharmaceuticals, NeuroSense, Emyria and more reporting updates in solid tumors, migraine, amyotrophic lateral sclerosis...
by marcbacon | Sep 21, 2022
By Joseph Keenan · Sep 21, 2022 · Fierce Biotech Australian biotech Emyria and U.S.-based CRO PsychoGenics have agreed to a collaborate on preclinical trials of MDMA-inspired drug candidates. Along with its partner, the University of Western Australia, Emyria will...
by Kelly Morris | Aug 23, 2022
by marcbacon | Aug 17, 2022
PsychoGenics uses a high-throughput platform comprising cameras and AI to analyze the behaviors of mice given a drug candidate before comparing them to a reference database. The platform enables the development of novel neuropsychiatric drugs and accelerates drug...
